Added to YB: 2025-04-24
Pitch date: 2025-04-22
ACHV [bullish]
Achieve Life Sciences, Inc.
+76.77%
current return
Author Info
No bio for this author
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$149.2M
Pitch Price
$2.54
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.09
P/E
-2.00
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Tailwinds Yeehee - Achieve Life Sciences, Inc.
ACHV: Developing Cystinicline for nicotine cessation - 2x higher quit rates than Varenicline with better safety profile. Potential for $1B+ sales (vs. discontinued Chantix's $1B in 2019). FDA Breakthrough Designation enables 6-month review with NDA submission June 2025, approval expected end-2025. $80M market cap undervalues opportunity.
Read full article (1 min)